Secukinumab for PASS syndrome: A new choice for therapeutic challenge?. Issue 7 (27th April 2022)

• Record Type: Journal Article
• Authors: Li, Mengmeng; Xiang, Hongmei; Liang, Yuxiang; Xue, Li; Zhou, Xingli; Yang, Lirong; Liu, Hongjie; Yang, Min; Tang, Jing; Li, Wei
• Is Part Of: Dermatologic therapy. Volume 35:Issue 7(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-27
• Subjects: hidradenitis suppurativa -- PASS syndrome -- pyoderma gangrenosum -- secukinumab -- spondyloarthritis; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15507
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: PASS syndrome is a rare inflammatory disease characterized by a chronic‐relapsing course of pyoderma gangrenosum, acne vulgaris, hidradenitis suppurativa, and spondyloarthritis, which is lack of any biological or genetic marker. Moreover, the optimal therapeutic management remains unclear. We herein describe a Yi Chinese man with PASS syndrome who was treated with secukinumab and showed a remarkable response with almost complete clinical improvement at the 2‐year follow‐up.